Author

Gemma E. Logan

Almac (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A.R. Phillips· 1 shared Alice T. Browne· 1 shared Alyson SpeediD· 1 shared Carla P. MartinsiD· 1 shared Catherine Joan Davidson· 1 shared Chris McCann· 1 shared Connor N. BrowniD· 1 shared Deborah Y. Moss· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A.R. Phillips

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Mutant KRAS dosage contributes to heterogeneity in lung cancer therapeutic response

Alice T. Browne, Chris McCann, William J. McDaid, Nikita Lewis, Sandhya Sridhar, Gary Joseph Doherty, Deborah Y. Moss, Matilda Downs, Stephen Marry, A.R. Phillips, Connor N. Brown, Alyson Speed, Gemma E. Logan, Gera L. Jellema, James R. Bradford, , Emma M. Kerr

This study shows that mutant KRAS dosage affects therapeutic response in lung cancer, with higher dosages linked to resistance to platinum therapy and sensitivity to pS6K inhibition.

bioRxiv · May 9, 2026 · PreprintCancer Biology